GMP Audit and QA in Bangladesh

A DGDA licence lets you sell here. It does not travel.

Bangladesh’s drug regulator applied for PIC/S pre-accession in February 2019 and is still an applicant, working towards membership around 2030. Until that lands, no overseas inspectorate is obliged to accept a DGDA inspection. So for anyone exporting medicines, supplements, disposables, food-contact goods or cosmetics, the question is never whether you hold a GMP certificate. It is whose GMP, and who has to believe it.

Standards we audit against

Not sure which one applies to your product? That is the first question an assessment answers, and it is answered before anyone walks the floor.

Scope

Five Product Families, Five Different Rulebooks

The phrase GMP audit covers at least five regimes, and they share neither a regulator, a standard nor an inspection style. Most disappointments start with a plant audited against the wrong one.

Pharmaceuticals and API

DGDA licence at home. WHO GMP and a CoPP for most export markets. EU GMP or an FDA inspection where the buyer is regulated there.

Nutraceuticals

Classified by the claim, not by the ingredient. The same capsule can sit under food rules or drug rules depending on what the label says.

Medical disposables

ISO 13485 is the system buyers ask for. Cleanroom classification and sterilisation validation are what they actually inspect.

Food-grade and food contact

HACCP plus whichever GFSI scheme your buyer has standardised on. Migration and food-contact material evidence, not only hygiene.

Cosmetics

ISO 22716 cosmetic GMP. Lighter than pharma on validation, heavier than most factories expect on batch traceability.

Mutual recognition

Whose GMP, And Who Is Obliged To Accept It

A certificate is worth exactly the jurisdictions that recognise it. These three tiers are not interchangeable, and the cost of moving between them is not linear.

Tier one

DGDA licence and GMP

Required to manufacture and sell inside Bangladesh, and issued after a DGDA inspection. Because the regulator is still a PIC/S pre-accession applicant rather than a member, that inspection carries no automatic weight with a foreign authority.

Tier two

WHO GMP and a CoPP

The practical passport for many semi-regulated markets and the usual first step up from a domestic licence. It opens tenders and registrations across much of Asia, Africa and Latin America. It does not open the European Union or the United States.

Tier three

EU GMP or a US FDA inspection

Granted only after that authority inspects your site itself. A small number of Bangladeshi plants hold one. It is the only route into the regulated markets, and the gap is far less about equipment than about quality systems and records.

The honest version: we are not a certification body and cannot issue any of the three. What we do is find, before an inspector does, the findings that would stop you being granted one, and write them down with a date, an owner and the clause they sit under.

Where sites actually fail

Inspectors Rarely Fail You On The Factory. They Fail You On The File.

It is tempting to prepare for an inspection by repainting the corridor and polishing the machines. The published enforcement record points somewhere else entirely.

A quality unit not following its own procedures

The most frequently cited US FDA observation in recent years has been failure to follow quality control unit procedures under 21 CFR 211.22(d). Not a missing procedure. One that exists and is not followed.

Discrepancies closed without a real investigation

The next most cited provision, 211.192, is the duty to thoroughly investigate any unexplained discrepancy. An out-of-specification result closed as analyst error with nothing behind it is the classic finding.

Records an inspector cannot trust

By most published counts data integrity now appears in a large majority of FDA drug GMP warning letters. Shared logins, audit trails that can be switched off, and paper filled in after the fact are the usual mechanics.

None of these three need new equipment to fix. All three need somebody to read your own records the way an inspector reads them, which is the part nobody enjoys and the part that decides the outcome.

The engagement

What A GMP Gap Assessment Produces

One standard named at the start, one written report, and nothing in it presented as a pass.

The standard fixed first

We agree which rulebook you are being measured against before anyone walks the floor, because the same observation can be minor under one and critical under another.

Data integrity walkthrough

Audit trails, user access and shared accounts, and the full route from a raw chromatogram to the number written in your batch record.

Mock inspection in the inspector's order

Opening meeting, document room, floor, laboratory, closing meeting. Run in the sequence and the tone a real inspection uses, not as a friendly tour.

Validation and stability review

Process, cleaning and analytical method validation, and the stability programme, examined as documents rather than accepted as claims.

Findings written to the clause

Every observation carries the clause it breaches, the evidence actually seen, a criticality grading and a named owner inside your organisation.

CAPA plan and a re-check

Dated actions with owners, then a return visit to verify closure, rather than accepting an email that says it has been done.

Questions manufacturers ask first

GMP Audit And QA: Straight Answers

For some destinations yes, for the ones worth most no. Bangladesh’s regulator applied for PIC/S pre-accession in 2019 and remains an applicant, so a DGDA inspection is not automatically recognised abroad. Many importing countries will register your product on a WHO GMP certificate and a Certificate of Pharmaceutical Product. The European Union and the United States will not: they inspect the site themselves.

Yes, and the harder question is which ones. A nutraceutical is usually classified by the claim on its label rather than by what is inside the capsule, so the same product can fall under food rules in one market and drug rules in another. We fix the classification for each target market before auditing, because auditing a supplement line against the wrong regime produces a report nobody can use.

Usually not the one companies expect. The long pole is rarely a machine; it is documented process validation, a working deviation and CAPA system, and a stability programme with real data behind it. Those take months of running, not weeks of preparation. A gap assessment exists to tell you which of them you are actually missing, so you spend the money on the right thing.

Not the system itself, but it changes what you will be selling. Bangladesh is scheduled to graduate from least developed country status on 24 November 2026, with a deferral request pending as this is written. Graduation ends the WTO TRIPS pharmaceutical waiver, which otherwise runs to the start of 2033 but only for countries that remain LDCs. Whatever date is finally fixed, the direction is the same: less room to formulate patented molecules at home, and more reason to compete on regulated-market exports, which are inspected to EU GMP or FDA standards rather than to a domestic licence.

We audit. We are not a certification body and cannot issue a DGDA, WHO, EU or FDA approval, and you should be wary of anyone in this market who implies otherwise. What an independent assessment gives you is the finding list before the regulator writes it, graded, clause-referenced and owned, so that the inspection you pay for is not the one that teaches you where the problems are.

A single-site assessment against one named standard is usually three to five days on site, with the report a week after. Multi-building sites and sterile lines take longer. To scope it we need your current licences with expiry dates, the last inspection report you received from anyone, a site plan with the manufacturing areas marked, and a clear statement of which markets you are aiming at.

Next step

Name The Standard. Then We Walk The Floor.

Tell us the markets you are aiming at and we will tell you which rulebook you are about to be measured against, what it will take to get there, and whether the honest answer is that you are not ready yet.

What we need to scope it